Residency · Los Angeles, CA
Sponsored by UCLA David Geffen School of Medicine/UCLA Medical Center
Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma.
The New England journal of medicine · 2023 · 643 citations · Timothy Cloughesy
Prostate Cancer, Version 4.2023, NCCN Clinical Practice Guidelines in Oncology.
Journal of the National Comprehensive Cancer Network : JNCCN · 2023 · 555 citations · Robert Reiter
Prostate cancer.
Nature reviews. Disease primers · 2021 · 942 citations · Robert Reiter
RANO 2.0: Update to the Response Assessment in Neuro-Oncology Criteria for High- and Low-Grade Gliomas in Adults.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023 · 468 citations · Timothy Cloughesy
Hepatobiliary Cancers, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.
Journal of the National Comprehensive Cancer Network : JNCCN · 2021 · 829 citations · Steven Raman
GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas.
Nature · 2022 · 697 citations · Kristen Yeom
Intravenous and intracranial GD2-CAR T cells for H3K27M+ diffuse midline gliomas.
Nature · 2025 · 172 citations · Kristen Yeom
Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: An international randomized phase III trial.
Neuro-oncology · 2023 · 466 citations · Timothy Cloughesy